Phase 2 Central Nervous System Lymphoma Clinical Trials
29 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 29 trials
Recruiting
Phase 2
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
Primary Central Nervous System LymphomaPCNSL
Tongji Hospital77 enrolled4 locationsNCT07350850
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1Phase 2
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more
Jonsson Comprehensive Cancer Center24 enrolled3 locationsNCT05256641
Recruiting
Phase 2
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1Phase 2
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Medical College of Wisconsin100 enrolled1 locationNCT04186520
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Phase 2
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 1Phase 2
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Central Nervous System Lymphoma
Tong Chen, MD30 enrolled5 locationsNCT05698147
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in Relapse+4 more
Essen Biotech75 enrolled1 locationNCT06213636
Recruiting
Phase 1Phase 2
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT06556199
Recruiting
Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Primary Central Nervous System LymphomaNon-Hodgkin Lymphoma of Extranodal Site
Lakshmi Nayak, MD25 enrolled2 locationsNCT04906096
Recruiting
Phase 2
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Primary Central Nervous System Lymphoma
Providence Health & Services28 enrolled7 locationsNCT06175000
Recruiting
Phase 2
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
Primary Central Nervous System Lymphoma (PCNSL)
Sichuan University34 enrolled1 locationNCT07014943
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+5 more
Miltenyi Biomedicine GmbH248 enrolled25 locationsNCT04792489
Recruiting
Phase 2
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Primary Central Nervous System Lymphoma
Henan Cancer Hospital30 enrolled1 locationNCT04737889
Recruiting
Phase 2
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Central Nervous System Lymphoma
Henan Cancer Hospital30 enrolled1 locationNCT05209620
Recruiting
Phase 2
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
Primary Central Nervous System Lymphoma
Kyorin University92 enrolled1 locationNCT06940791
Recruiting
Phase 1Phase 2
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaCNS Lymphoma
James Rubenstein35 enrolled1 locationNCT05351593